Intech Investment Management LLC Makes New $422,000 Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Intech Investment Management LLC purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 48,483 shares of the biopharmaceutical company’s stock, valued at approximately $422,000.

Several other large investors have also recently made changes to their positions in OCUL. Vanguard Group Inc. increased its position in Ocular Therapeutix by 41.4% during the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after acquiring an additional 2,117,029 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Ocular Therapeutix by 1,142.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock worth $6,031,000 after buying an additional 609,328 shares during the period. Cetera Investment Advisers boosted its position in Ocular Therapeutix by 6.5% during the 1st quarter. Cetera Investment Advisers now owns 725,990 shares of the biopharmaceutical company’s stock valued at $6,607,000 after acquiring an additional 44,590 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Ocular Therapeutix in the 2nd quarter worth $5,130,000. Finally, Deltec Asset Management LLC boosted its position in Ocular Therapeutix by 9.6% during the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock valued at $17,717,000 after purchasing an additional 226,181 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Trading Down 1.2 %

Ocular Therapeutix stock opened at $9.77 on Tuesday. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock’s 50 day simple moving average is $10.00 and its two-hundred day simple moving average is $8.30. Ocular Therapeutix, Inc. has a 12 month low of $2.88 and a 12 month high of $11.77. The firm has a market cap of $1.54 billion, a PE ratio of -7.40 and a beta of 1.26.

Analyst Ratings Changes

Several analysts have recently commented on OCUL shares. Scotiabank started coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price objective for the company. Robert W. Baird dropped their target price on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, HC Wainwright raised their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.